Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, ...
Stocks See Support as Bond Yields Fall on Fed Rate Cut Optimism
Charting, Price Performance, News & Related Contracts.
The Globe and Mail59m
Stocks See Support from Fed-Friendly US Economic Reports
Biomea Fusion (BMEA) is up more than +20% after Truist Securities upgraded the stock to buy from hold with a price target of $54. Establishment Labs Holdings (ESTA) is up more than +14% after it ...